Expanding the Donor Pool and Developing Alternative Grafts

25 concepts24 papers1 proposal

Organ transplantation is a victim of its own success. While surgical techniques have advanced to the point where replacing a failing organ is a standard life-saving procedure, the global supply of deceased-donor organs comes nowhere near meeting the clinical demand. This chronic supply-demand gap results in thousands of deaths annually for patients waiting for kidneys, lungs, and livers.

To bypass this bottleneck, researchers are attacking the problem from multiple angles: maximizing the utility of existing human tissue, using machine learning to salvage marginal organs, engineering cross-species and synthetic alternatives, and developing "bridge therapies" that protect failing organs to eliminate the need for transplantation entirely.


Maximizing Human Tissue: Splitting and Living Donors

The most immediate way to address organ scarcity is to extract more metabolic capacity from the available human donor pool. Because the liver possesses an extraordinary ability to regenerate, a single liver can theoretically be divided to save more than one life, or a healthy individual can safely donate a portion of their own organ.

Historically, Living Donor Liver Transplantation (LDLT) was confined to pediatric recipients who required only small graft volumes. As reviewed by Koichi Tanaka in Progress and future in living donor liver transplantation., innovations like right-lobe grafting and microsurgical artery reconstruction allowed surgeons to scale this approach to adults, establishing LDLT as a primary alternative to deceased-donor waiting lists. Similarly, in renal transplantation, YL Hong et al. demonstrated in Characteristics and clinical outcomes of living renal donors in Hong Kong that transitioning to laparoscopic techniques minimized donor risks while the remaining kidney reliably compensated over the long term.

However, relying on partial grafts introduces severe physiological constraints. As C Lo et al. point out in Topic-1b: Technical aspects and physiological problems in split/living donor liver transplantation, a partial liver segment must provide immediate, sufficient metabolic capacity for an adult recipient without succumbing to "small-for-size syndrome," where excessive portal vein pressure damages the graft.

To mitigate these risks, modern strategies focus on precise anatomical splitting and donor-recipient matching. Qiang Sun et al. showed in Adult split liver transplantation to treat liver cancer: a single-center retrospective study that split liver transplantation (SLT)—dividing a single deceased-donor liver for two adult recipients—can achieve survival rates and complication profiles equivalent to whole-graft transplants. Furthermore, Liangshuo Hu et al. demonstrated in Child-to-Adult Liver Transplantation With Donation After Cardiac Death Donors that even smaller pediatric livers from donors after circulatory death can safely support adult recipients, provided intraoperative portal vein pressure is strictly monitored to prevent congestion.


Algorithmic Salvage: Objective Organ Assessment

A significant portion of the organ shortage is artificial: clinicians frequently discard "marginal" organs—those from older donors or with minor abnormalities—to avoid post-operative complications. Because human assessment is inherently subjective and conservative, many viable organs are thrown away.

To solve this, researchers are combining ex vivo organ perfusion with machine learning. Ex vivo perfusion keeps an organ alive outside the body by circulating warm, oxygenated blood or nutrient solutions through it, allowing clinicians to observe its function in real time.

[Marginal Donor Organ] 
       │
       ▼
[Ex Vivo Perfusion System] ──► (Continuous Functional Data: Flow, Pressure, Biomarkers)
       │
       ▼
[InsighTx (ML Model)] ──────► Objective Viability Score ──► [Safe Transplantation]

In A machine-learning approach to human ex vivo lung perfusion predicts transplantation outcomes and promotes organ utilization, Andrew T. Sage et al. introduced InsighTx, a machine-learning model that analyzes the complex, continuous data streams generated during ex vivo lung perfusion. By identifying subtle physiological patterns that elude human eyes, the model predicts transplant success far more accurately than standard clinical assessments. This objective data gives surgeons the confidence to utilize marginal organs that would otherwise be discarded, safely expanding the donor pool without compromising patient safety.


Engineering Alternative Grafts: Xenotransplantation and Bioprinting

When human tissue optimization reaches its absolute limit, the field must look to non-human or synthetic alternatives. The two primary frontiers are xenotransplantation (using animal organs) and 3D bioprinting.

Xenotransplantation has historically been blocked by hyperacute rejection, where the human innate immune system immediately recognizes animal cells as foreign and destroys them via complement-mediated cytotoxicity. Early research, such as the work by Shin Itakura et al. in Cytotoxicity for Porcine Islet Cells by Complement of Six Animal Species, mapped how different animal complements attack porcine cells, highlighting the severity of this immunological barrier.

The advent of CRISPR gene editing changed the landscape by allowing scientists to knock out the specific pig genes responsible for triggering this immune response. As documented by Zhen Geng et al. in INTERNATIONAL HUMAN XENOTRANSPLANTATION INVENTORY: THE ADVENT OF CLINICAL TRIALS, the field has recently transitioned into human clinical trials using genetically modified pig hearts and kidneys. Crucially, Xueyun Huo et al. demonstrated in Genome-wide Genetic Mutations Accumulated in Pigs Genome-edited for Xenotransplantation and Their Filial Generation that while these edited founder pigs accumulate thousands of off-target mutations, the mutations are largely non-coding and are stably inherited by subsequent generations without altering gene expression or animal health. This proves that gene-edited pigs can be safely bred at scale to provide a predictable, unlimited supply of organs.

Concurrently, 3D bioprinting aims to eliminate biological donors entirely. As reviewed by Huiyu Zhou in Current Situation of 3D Bio-printing Technology, the technology has evolved from simple structural scaffolds to printing complex, multi-material tissues embedded with living cells. For patients requiring radical surgeries—such as a nephrectomy for renal cell carcinoma—Yehao Li notes in Progress on Pathogenesis Rccs and Related Treatments that the development of bioengineered, artificial kidneys represents the ultimate frontier to resolve post-surgical organ bottlenecks.


Downscaling Demand: Bridge Therapies for Acute Failure

An alternative way to solve the organ shortage is to reduce the number of patients who need a transplant in the first place. In conditions like Acute Liver Failure (ALF), hepatocytes die rapidly, triggering a massive, systemic inflammatory response. However, if the patient can be kept alive through this acute crisis, the liver's natural regenerative capacity can often restore full function.

Recent work reveals that stem cell therapies can act as a powerful "bridge" during these crises. Crucially, these cells do not work by structurally replacing the damaged tissue. Instead, they function as immunomodulatory factories.

[Acute Liver Failure] ──► [Monocyte Activation] ──► [Lethal Cytokine Storm] ──► [Death / Transplant]
                                                              ▲
                                                      (Inhibition via IL-6)
                                                              │
                                                [Mesenchymal Stem Cells (MSCs)]

Gang Guo demonstrated this mechanism in Peripheral infusion of human umbilical cord mesenchymal stem cells rescues acute liver failure lethality in monkeys, showing that an infusion of human umbilical cord mesenchymal stem cells (hUC-MSCs) rescued 100% of monkeys from lethal ALF. The stem cells migrated to the site of injury and shut down the lethal "cytokine storm" by suppressing circulating monocytes.

To optimize these therapies, researchers are mapping the exact molecular signals driving this protection:

Beyond cell therapies, small molecules and microbiome interventions are being developed to arrest acute organ failure before it becomes irreversible. Xia Gong et al. showed that the herbal compound tetrandrine significantly reduces mortality in fulminant hepatic failure by suppressing inflammatory pathways in Tetrandrine attenuates lipopolysaccharide-induced fulminant hepatic failure in d-galactosamine-sensitized mice. Similarly, Zhenxing He et al. found that the citrus flavonoid nobiletin mitigates acute liver injury by simultaneously activating the Nrf2 antioxidant pathway and shutting down NF-κB-mediated cytokine production in Nobiletin attenuates lipopolysaccharide/D-galactosamine-induced liver injury in mice by activating the Nrf2 antioxidant pathway and subsequently inhibiting NF-κB-mediated cytokine production. Finally, Chunchun Yuan et al. demonstrated in Integrated Analysis of Gut Microbiome and Liver Metabolome to Evaluate the Effects of Fecal Microbiota Transplantation on Lipopolysaccharide/D-galactosamine-Induced Acute Liver Injury in Mice that Fecal Microbiota Transplantation (FMT) can stabilize the gut-liver axis, reducing hepatic inflammation and cell apoptosis.

By combining immediate surgical and algorithmic optimizations with long-term genetic, synthetic, and therapeutic innovations, modern medicine is steadily moving toward a future where the availability of a donor organ is no longer the limiting factor in patient survival.

Key Foundational Work

Progress and future in living donor liver transplantation. (2003) — contributed 1 concept elements to this direction.
Topic-1b: Technical aspects and physiological problems in split/living donor liver transplantation (2001) — contributed 1 concept elements to this direction.
Application of False Discovery Rate Control in the Assessment of Decrease of FDG Uptake in Early Alzheimer Dementia (2003) — contributed 1 concept elements to this direction.
History & citationVersion 1 · 2026-10-04

Current · Permanent link

View frozen version 1

Cite this direction

Latest version (a living page):

@misc{lacuna_donor_organ_scarcity_13e04081,
  title = {donor organ scarcity},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/donor-organ-scarcity/rdr_13e040814619489dbf8d4c50f36fab69},
  note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-19},
}

This exact version (version 1, frozen text):

@misc{lacuna_donor_organ_scarcity_13e04081_v1,
  title = {donor organ scarcity},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/donor-organ-scarcity/rdr_13e040814619489dbf8d4c50f36fab69/v/1},
  note = {Version 1, frozen 2026-10-04. Accessed 2026-11-19},
}
About

These directions overlap with this one through shared papers.

See something wrong? Report a mistake